TDMS Study 05087-03 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
TRIAMTERENE
NTP Experiment-Test: 05087-03 Report: PEIRPT05
Study Type: CHRONIC Date: 09/11/94
Route: DOSED FEED Time: 15:25:20
Facility: Battelle Columbus Laboratory
Chemical CAS #: 396-01-0
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05087-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIAMTERENE Date: 09/11/94
Route: DOSED FEED Time: 15:25:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 400 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60
Scheduled Sacrifice 10 9
Early Deaths
Natural Death 3 9
Moribund Sacrifice 7 4
Survivors
Terminal Sacrifice 40 38
Animals Examined Microscopically 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (60) (59)
Intestine Large, Cecum (59) (60)
Intestine Large, Colon (60) (60)
Fibrosarcoma, Metastatic, Uterus 1 (2%)
Intestine Large, Rectum (60) (59)
Intestine Small, Ileum (59) (60)
Intestine Small, Jejunum (59) (60)
Liver (60) (60)
Hepatocellular Carcinoma 6 (10%) 9 (15%)
Hepatocellular Carcinoma, Multiple 2 (3%)
Hepatocellular Adenoma 4 (7%) 9 (15%)
Hepatocellular Adenoma, Multiple 3 (5%) 19 (32%)
Pancreas (59) (59)
Salivary Glands (60) (60)
Stomach, Forestomach (60) (60)
Squamous Cell Papilloma 1 (2%)
Stomach, Glandular (60) (60)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (60) (60)
Spindle Cell, Adenoma 2 (3%) 2 (3%)
Adrenal Gland, Medulla (59) (60)
Islets, Pancreatic (59) (57)
Adenoma 1 (2%)
Page 2
NTP Experiment-Test: 05087-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIAMTERENE Date: 09/11/94
Route: DOSED FEED Time: 15:25:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 400 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Pituitary Gland (59) (56)
Adenoma 1 (2%) 1 (2%)
Pars Distalis, Adenoma 2 (4%)
Pars Distalis, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (7) (4)
Hemangiosarcoma 1 (14%)
Ovary (60) (58)
Granulosa Cell Tumor Benign 1 (2%)
Teratoma Benign 1 (2%)
Uterus (60) (60)
Adenocarcinoma 1 (2%)
Fibrosarcoma 1 (2%)
Hemangiosarcoma 1 (2%)
Leiomyosarcoma 1 (2%)
Sarcoma Stromal 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Lymph Node (60) (60)
Lymph Node, Mandibular (60) (60)
Mast Cell Tumor Malignant 1 (2%)
Lymph Node, Mesenteric (57) (56)
Spleen (59) (60)
Hemangiosarcoma 3 (5%)
Thymus (56) (52)
Fibrosarcoma, Metastatic, Bone 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (60) (60)
Subcutaneous Tissue, Mast Cell Tumor
Malignant 1 (2%)
Subcutaneous Tissue, Myxosarcoma 1 (2%)
Subcutaneous Tissue, Neurofibrosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 3
NTP Experiment-Test: 05087-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIAMTERENE Date: 09/11/94
Route: DOSED FEED Time: 15:25:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 400 PPM
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (60) (59)
Fibrosarcoma 2 (3%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (60)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60)
Alveolar/Bronchiolar Adenoma 2 (3%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 4 (7%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (4) (4)
Adenoma 3 (75%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (60)
Urinary Bladder (60) (59)
Fibrosarcoma, Metastatic, Uterus 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60)
Lymphoma Malignant Histiocytic 3 (5%)
Lymphoma Malignant Lymphocytic 1 (2%) 2 (3%)
Lymphoma Malignant Mixed 8 (13%) 12 (20%)
Lymphoma Malignant Undifferentiated Cell 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 4
NTP Experiment-Test: 05087-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIAMTERENE Date: 09/11/94
Route: DOSED FEED Time: 15:25:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 400 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 30 45
Total Primary Neoplasms 41 73
Total Animals with Benign Neoplasms 12 31
Total Benign Neoplasms 13 39
Total Animals with Malignant Neoplasms 24 30
Total Malignant Neoplasms 28 34
Total Animals with Metastatic Neoplasms 2 5
Total Metastatic Neoplasm 2 6
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 5
NTP Experiment-Test: 05087-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIAMTERENE Date: 09/11/94
Route: DOSED FEED Time: 15:25:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 400 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 60 60
Scheduled Sacrifice 10 10
Early Deaths
Natural Death 4 7
Moribund Sacrifice 3 4
Survivors
Natural Death 1
Terminal Sacrifice 42 39
Animals Examined Microscopically 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (58) (58)
Intestine Large, Cecum (59) (60)
Fibrosarcoma 1 (2%)
Intestine Large, Colon (58) (60)
Intestine Large, Rectum (59) (60)
Intestine Small, Duodenum (57) (60)
Intestine Small, Jejunum (59) (59)
Liver (59) (60)
Hemangiosarcoma 2 (3%)
Hemangiosarcoma, Multiple 1 (2%)
Hepatoblastoma 1 (2%)
Hepatocellular Carcinoma 8 (14%) 8 (13%)
Hepatocellular Carcinoma, Multiple 1 (2%) 3 (5%)
Hepatocellular Adenoma 10 (17%) 13 (22%)
Hepatocellular Adenoma, Multiple 11 (19%) 24 (40%)
Mesentery (2) (1)
Adenocarcinoma 1 (50%)
Fibrosarcoma, Metastatic, Skeletal Muscle 1 (50%)
Pancreas (58) (60)
Fibrosarcoma, Metastatic, Skeletal Muscle 1 (2%)
Salivary Glands (60) (60)
Stomach, Forestomach (59) (60)
Stomach, Glandular (59) (60)
____________________________________________________________________________________________________________________________________
Page 6
NTP Experiment-Test: 05087-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIAMTERENE Date: 09/11/94
Route: DOSED FEED Time: 15:25:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 400 PPM
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60)
Fibrosarcoma, Metastatic, Skeletal Muscle 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (60) (60)
Spindle Cell, Adenoma 1 (2%)
Adrenal Gland, Medulla (60) (60)
Islets, Pancreatic (57) (59)
Adenoma 1 (2%)
Carcinoma 1 (2%)
Pituitary Gland (60) (57)
Pars Distalis, Adenoma 1 (2%)
Thyroid Gland (60) (60)
Follicular Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (60) (60)
Prostate (60) (60)
Seminal Vesicle (60) (60)
Testes (60) (60)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (60)
Hemangiosarcoma 1 (2%)
Lymph Node (60) (60)
Fibrosarcoma, Metastatic, Lymph Node 1 (2%)
Lymph Node, Mandibular (60) (60)
Lymph Node, Mesenteric (51) (54)
Spleen (57) (60)
Hemangiosarcoma 2 (4%)
Thymus (49) (52)
Fibrosarcoma, Metastatic, Skeletal Muscle 1 (2%)
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 05087-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIAMTERENE Date: 09/11/94
Route: DOSED FEED Time: 15:25:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 400 PPM
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (60) (60)
Osteosarcoma, Metastatic, Bone 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (60) (60)
Maxilla, Fibrosarcoma 1 (2%)
Vertebra, Coccygeal, Osteosarcoma 1 (2%)
Skeletal Muscle (1) (2)
Hindlimb, Fibrosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (60)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (59) (60)
Alveolar/Bronchiolar Adenoma 6 (10%) 9 (15%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 7 (12%) 5 (8%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Fibrosarcoma, Metastatic, Skeletal Muscle 1 (2%)
Hepatocellular Carcinoma, Multiple,
Metastatic 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 3 (5%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1)
Fibrosarcoma 1 (100%)
Harderian Gland (5) (6)
Adenoma 1 (20%) 6 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (60)
Carcinoma 1 (2%)
Fibrosarcoma, Metastatic, Skeletal Muscle 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Page 8
NTP Experiment-Test: 05087-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIAMTERENE Date: 09/11/94
Route: DOSED FEED Time: 15:25:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 400 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - cont
Artery, Hepatocellular Carcinoma, Metastatic 1 (2%)
Urinary Bladder (60) (60)
Papilloma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(60) *(60)
Lymphoma Malignant Histiocytic 1 (2%)
Lymphoma Malignant Mixed 5 (8%) 8 (13%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 9
NTP Experiment-Test: 05087-03 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIAMTERENE Date: 09/11/94
Route: DOSED FEED Time: 15:25:20
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 400 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 38 45
Total Primary Neoplasms 64 85
Total Animals with Benign Neoplasms 26 40
Total Benign Neoplasms 30 57
Total Animals with Malignant Neoplasms 25 26
Total Malignant Neoplasms 34 28
Total Animals with Metastatic Neoplasms 4 4
Total Metastatic Neoplasm 10 6
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 10
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------